Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata causes hair loss with varied treatment responses and frequent relapses.

Higher RBP4 levels found in people with two types of hair loss.

Chemotherapy often causes temporary hair loss, which is distressing and needs better treatment and support.

Overexpressing the mineralocorticoid receptor in mouse skin causes skin thinning, early skin barrier development, eye issues, and hair loss.

The study found that immune responses disrupt hair growth cycles, causing hair loss in alopecia areata.

A new type of sudden, complete female hair loss was found, with most patients fully recovering within 6 months without needing steroid treatment.

A man had temporary hair loss from radiation during a medical procedure but regrew his hair after treatment with minoxidil lotion.

Lupus can affect the scalp and nails, often causing hair loss and nail damage, and needs early aggressive treatment to prevent permanent damage.

Alopecia areata involves immune response and gene changes affecting hair loss.

Stress can cause a type of hair loss in mice lacking the CCHCR1 gene.

The hepatitis B vaccine did not cause hair loss in the tested mice.

Scalp cooling is the most effective FDA-approved method to prevent chemotherapy-induced hair loss, but more research is needed for other treatments.

A gene in Sebekia benihana, CYP-sb21, is needed for a specific reaction on the drug Cyclosporine A, which could be important for hair growth without affecting the immune system.

The document concludes that more research is needed to better understand and treat primary cicatricial alopecias, and suggests a possible reclassification based on molecular pathways.

Alopecia areata is likely caused by a combination of genetic factors and immune system dysfunction, and may represent different diseases with various causes.

Despite progress in treatment, the exact cause of Alopecia areata is still unknown.

Gonadal hormones significantly affect the severity of alopecia areata in mice.

Patchy alopecia areata can affect only pigmented hairs, leaving gray hairs untouched.

The cause of alopecia areata is likely a mix of genetics, immune system issues, and environmental factors, with more research needed to understand it fully.

Experts agreed on guidelines to improve research on Frontal Fibrosing Alopecia.

New treatments for Alopecia Areata show promise but need to be more effective and affordable.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

New treatments for hair loss should target eight main causes and use specific plant compounds and peptides for better results.

The 2015 Hair Research Congress concluded that stem cells, maraviroc, and simvastatin could potentially treat Alopecia Areata, topical minoxidil, finasteride, and steroids could treat Frontal Fibrosing Alopecia, and PTGDR2 antagonists could also treat alopecia. They also found that low-level light therapy could help with hair loss, a robotic device could assist in hair extraction, and nutrition could aid hair growth. They suggested that Alopecia Areata is an inflammatory disorder, not a single disease, indicating a need for personalized treatments.

Chemotherapy can cause skin side effects that affect patients' lives, but they can be managed to avoid interrupting cancer treatment.

Enzymes called PADIs play a key role in hair growth and loss.

A topical lotion helped manage hair loss from chemotherapy by affecting cell death, inflammation, and collagen, with no side effects.

Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.

The document concludes that Telogen Effluvium is a hair loss disorder that can be assessed with the modified wash test and may be treated with clobetasol foam, with patient management being important.

People with hair loss conditions often have more mental health issues like depression and anxiety compared to those without hair loss.